Vaccinex, Inc. Files 8-K: Material Agreement & Equity Sales
Ticker: VCNX · Form: 8-K · Filed: Sep 19, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Sep 19, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $7.64, $32.76, $5.636, $0.125 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Vaccinex filed an 8-K on 9/17 for a material agreement and equity sales.
AI Summary
On September 17, 2024, Vaccinex, Inc. filed an 8-K report detailing a material definitive agreement. The filing also covers unregistered sales of equity securities and includes financial statements and exhibits. The company is incorporated in Delaware and headquartered in Rochester, NY.
Why It Matters
This 8-K filing indicates significant corporate activity, including a new material agreement and equity transactions, which could impact the company's financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered equity sales, which can introduce financial and regulatory risks.
Key Numbers
- 001-38624 — Commission File Number (Identifies the company's SEC filing history)
- 16-1603202 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- September 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Rochester, New York (location) — Principal executive offices
- 1895 Mount Hope Avenue (address) — Principal executive offices street
- 14620 (zip_code) — Principal executive offices zip code
- (585) 271-2700 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in this excerpt.
What type of equity securities were sold unregistered?
The filing states 'Unregistered Sales of Equity Securities' but does not specify the type or amount of securities sold in this excerpt.
When was the earliest event reported in this 8-K?
The earliest event reported is dated September 17, 2024.
Where are Vaccinex, Inc.'s principal executive offices located?
Vaccinex, Inc.'s principal executive offices are located at 1895 Mount Hope Avenue, Rochester, New York 14620.
What is Vaccinex, Inc.'s SIC code?
Vaccinex, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,106 words · 4 min read · ~4 pages · Grade level 12.7 · Accepted 2024-09-19 08:30:30
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
- $7.64 — ch 2024, having exercise prices between $7.64 and $32.76 per share (the "Existing War
- $32.76 — aving exercise prices between $7.64 and $32.76 per share (the "Existing Warrants"). Pu
- $5.636 — Warrants at a reduced exercise price of $5.636 per share in consideration of the Compa
- $0.125 — ld in a private placement at a price of $0.125 per New Warrant. Each New Warrant has a
- $6.2 m — e of the New Warrants are approximately $6.2 million, prior to deducting financial adv
Filing Documents
- d836959d8k.htm (8-K) — 31KB
- d836959dex41.htm (EX-4.1) — 94KB
- d836959dex101.htm (EX-10.1) — 49KB
- 0001193125-24-221790.txt ( ) — 335KB
- vcnx-20240917.xsd (EX-101.SCH) — 3KB
- vcnx-20240917_lab.xml (EX-101.LAB) — 17KB
- vcnx-20240917_pre.xml (EX-101.PRE) — 11KB
- d836959d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. The following exhibits are filed herewith: Exhibit Number Exhibit Description 4.1 Form of Common Stock Purchase Warrant, dated September 18, 2024 10.1 Form of Inducement Letter Agreement, by and between the Company and each purchaser identified on the signature pages thereto, dated as of September 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Vaccinex, Inc. Date: September 19, 2024 By: /s/ Maurice Zauderer Maurice Zauderer Chief Executive Officer